Faeth Therapeutics (FTH) Cash from Operations (2020 - 2026)

Faeth Therapeutics (FTH) has reported Cash from Operations for 7 consecutive years, with -$15.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 165.24% year-over-year to -$15.7 million; the trailing twelve-month figure through Jun 2026 stood at -$33.9 million (down 39.53% YoY), and the FY2025 full-year result was -$20.5 million, up 17.09% from the prior year.
• Cash from Operations retreated to -$15.7 million in Q2 2026 per FTH's latest filing, from -$10.7 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$3.6 million in Q3 2025 and bottomed at -$15.7 million in Q2 2026.
• Historically, Cash from Operations has averaged -$7.9 million across 5 years, with a median of -$6.9 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash from Operations surged 38.79% in 2024, then slumped 165.24% in 2026.
• Over 5 years, Cash from Operations stood at -$9.6 million in 2022, then surged by 35.63% to -$6.2 million in 2023, then increased by 6.02% to -$5.8 million in 2024, then soared by 33.29% to -$3.9 million in 2025, then slumped by 305.62% to -$15.7 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$15.7 million, -$10.7 million, and -$3.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.